Furthermore, with patients suffering from ccRCC, anti-PD-1 drugs manifest limited efficacy in the elimination of metastases in the central nervous system, given the modest penetrance of the blood–brain barrier [7]. The gene discussed is PDCD1; the disease is nonpapillary renal cell carcinoma.